An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease

Keyzer-Dekker, C.M.G.; van Esch, L.; de Vries, J.; Ernst, M.F.; Nieuwenhuijzen, G.A.P.; Roukema, J.A.; van der Steeg, A.F.W.

Published in:
Breast Cancer Research and Treatment

DOI:
10.1007/s10549-012-2025-5

Publication date:
2012

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Tilburg University Research Portal

Citation for published version (APA):
Keyzer-Dekker, C. M. G., van Esch, L., de Vries, J., Ernst, M. F., Nieuwenhuijzen, G. A. P., Roukema, J. A., & van der Steeg, A. F. W. (2012). An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease. Breast Cancer Research and Treatment, 134(1), 253-258. https://doi.org/10.1007/s10549-012-2025-5
An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease

C. M. G. Keyzer-Dekker · L. van Esch · J. de Vries · M. F. Ernst · G. A. P. Nieuwenhuijzen · J. A. Roukema · A. F. W. van der Steeg

Received: 26 December 2011 / Accepted: 7 March 2012 / Published online: 21 March 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Being recalled for further diagnostic procedures after an abnormal screening mammogram (ASM) can evoke a high state anxiety with lowered quality of life (QoL). We examined whether these adverse psychological consequences are found in all women with benign breast disease (BBD) or are particular to women referred after ASM. In addition, the influence of the anxiety as a personality characteristic (trait anxiety) was studied. Between September 2002 and February 2010 we performed a prospective longitudinal study in six Dutch hospitals. Women referred after ASM or with a palpable lump in the breast (PL), who were subsequently diagnosed with BBD, were included. Before diagnosis (at referral) and during follow-up, questionnaires were completed examining trait anxiety (at referral), state anxiety, depressive symptoms (at referral, one, three and 6 months after diagnosis), and QoL (at referral and 12 months). Women referred after ASM (N = 363) were compared with women with PL (N = 401). A similar state anxiety score was found in both groups, but a lower psychological QoL score at 12 months was seen in the ASM group. In women with not-high trait anxiety those in the ASM group were more anxious with more depressive symptoms at referral, and reported impaired psychological QoL at referral and at 12 months compared with the PL group. No differences were found between ASM and PL in women with high trait anxiety, but this group scored unfavorably on anxiety, depressive symptoms and QoL compared with women with not-high trait anxiety. ASM evokes more anxiety and depressive symptoms and lowered QoL compared with women referred with PL, especially in women who are not prone to anxiety. Women should be fully informed properly about the risks and benefits of breast cancer screening programs. We recommend identifying women at risk of reduced QoL using a psychometric test.

Keywords False-positive · Screening mammogram · Anxiety · Depressive symptoms · Quality of life · Benign breast disease

Abbreviations

BC     Breast cancer
PL     Palpable lump in the breast
Introduction

Breast cancer (BC) is the most common cancer among women. In the western world, one in eight women is at risk of developing BC [1, 2]. However, the majority of women visiting the surgical outpatient clinic with breast problems, such as a palpable lump (PL) or an abnormal screening mammogram (ASM), are diagnosed with benign breast disease (BBD) [3]. During the investigation of breast symptoms, women experience increased anxiety and distress [4–6]. Even after a diagnosis of BBD is made, these symptoms persist in a proportion of women [4]. Women with BBD diagnosed after an ASM report ongoing anxiety [7–9] with lowered quality of life (QoL) [10, 11]. In chronically anxious women (i.e., with high trait anxiety), these psychological effects are heightened [6, 10, 12]. Trait anxiety refers to relatively stable individual differences in anxiety proneness [13].

Thus, it is important to evaluate women diagnosed with BBD as the lack of reassurance after the diagnostic work-up and adverse psychological consequences may result in lowered QoL. Although these effects on women with BBD have been previously studied, a comparison between women referred after an ASM or with PL has not been performed before. This comparison is important in the context of the ongoing discussions on whether the advantages of a BC screening program still outweigh the disadvantages (such as the false-positive findings) [14, 15]. Therefore, we examined whether all women with BBD (ASM and PL) experience similar levels of anxiety (state anxiety), depressive symptoms, and changes in QoL during and in the year following the diagnostic work-up. Women attending breast screening usually have no palpable lump in the breast and so are not expecting an ASM. We hypothesized that these women are more alarmed by being recalled for further diagnostic procedures and experience more adverse psychological effects compared with women with a PL. Based on previous studies, we also analyzed the influence of the personality characteristic trait anxiety [10, 16].

In this prospective, longitudinal study comparing ASM with PL, women completed the first set of questionnaires before any diagnostic procedures were performed (at referral).

Patients and methods

Participants

Women referred after an ASM or with a PL were eligible for participating in this study. The study was conducted between September 2002 and February 2010 in six Dutch hospitals. The Medical Ethical Committee of the primary research hospital, i.e., St. Elisabeth Hospital, Tilburg, approved the study protocol. This study was part of a larger study analyzing the impact of personality and QoL on morbidity, mortality, and health care consumption in breast disease. Women with recurrent BBD or BC, inability to read and write in Dutch, or (previous) psychiatric illness were excluded. When women were invited to participate in the study and completed the first set of questionnaires, the diagnosis was unknown. All participants gave written informed consent.

Since 1990, BC screening is offered every 2 years to women in the age between 50 and 75 years in the Netherlands. Every year one million women receive an invitation for BC screening mammogram. The overall attendance rate is 80 % [17]. Two-view mammography was used at initial BC screening. All women with an ASM were referred to a dedicated outpatient breast clinic.

Questionnaires

Questionnaires were completed at referral (before diagnosis was known), and one, three, six, and 12 months after diagnosis. The questionnaires assessed personality at referral (STAI-trait), experienced momentary anxiety (STAI-state) and depressive symptoms (CES-D) at referral until 6 months, and QoL (WHOQOL-bref) at referral and 12 months after diagnosis.

The state-and-trait-anxiety-inventory (STAI) measures two types of anxiety: trait and state. Trait anxiety refers to the tendency to respond to situations perceived as threatening with a rise in anxiety intensity. State anxiety refers to the amount of stress being experienced at the specific moment the measurement is made [13, 18]. In this study, the short 6-item state version and 10-item trait version of the STAI were used [19, 20]. High trait anxiety (HTA) was defined as a score greater than 22. The reliability and validity of the short versions are considered good [19, 20].

The Center for Epidemiological Studies-depression scale (CES-D) was used to assess depressive symptoms. It measures both the presence and the degree of depressive symptoms [21, 22]. The World Health Organization Quality of Life assessment instrument-Bref (WHOQOL-Bref) is a short version of the WHOQOL-100 [23, 24]. The WHOQOL-Bref consists of questions assessing QoL within four domains.
(physical health, psychological health, social relationships, and environment) and a general evaluative facet (overall QoL and general health). The psychometric properties of the WHOQOL-Bref have been demonstrated to be good in women with benign breast disease [3].

Women were also asked to complete a questionnaire concerning demographic characteristics. The medical data concerning patient and mammography characteristics were obtained from the medical records.

Statistics

Women who did not complete all questionnaires during follow up, were excluded from further analysis and considered as drop-outs. Chi-square tests and independent t tests were used to compare women in the non drop-out and drop-out groups, and in the ASM or PL groups with regard to demographic (age, children, marital status, paid work, and educational level) and personality (trait anxiety) characteristics at baseline. Differences in demographic characteristics were used as covariates in the subsequent analysis.

A repeated measures general linear model was used to examine scores on state anxiety and depressive symptoms (at referral until 6 months), and QoL (at referral and 12 months) across time (i) in the two groups ASM or PL, and (ii) in women with HTA or not-high score on trait anxiety (NHTA) in ASM or PL group. A P value <0.05 was considered statistical significant. All analyses were performed with the Statistical Package for Social Sciences (SPSS version 18.0).

Results

During the study period, 1145 women were diagnosed with BBD. During follow-up, 381 women did not complete all questionnaires, and were excluded from further analysis. Women in the drop-out group were less educated (P = 0.016) and scored higher on trait anxiety (P < 0.001) compared with the group that remained in the study. There was no difference concerning referral after ASM or PL.

In total, 764 women were analyzed at referral. 363 women in the ASM group, and 401 in the PL group. At referral, significant differences were observed concerning demographics between the two groups (Table 1). Women in the ASM group were older (P < 0.001), more often had children (P = 0.009), and less often had paid work (P < 0.001). There was no difference between the two groups concerning trait anxiety at referral.

At referral, the mean scores for state anxiety were comparable in the ASM and PL groups (P = 0.074; Table 1). In both groups, the state anxiety scores significantly decreased after 1 month compared with the scores at referral (P < 0.001; Table 1). Concerning depressive symptoms, a higher mean score was found in ASM compared with PL at referral (P = 0.007), in both groups scores significantly decreased at 1 month compared with the scores at referral (P < 0.001; Table 1). After 1 month, no differences between the two groups were found. From 1 month follow-up scores on state anxiety and depressive symptoms remained similar until 6 months in both groups (Table 1). Concerning the scores on QoL, there were no differences between the AS and the PL groups at referral. At 12 months, women in the ASM group scored lower on psychological QoL (P = 0.022) compared with the PL group.

In the subanalysis, women were divided in four groups based on referral after ASM or with PL and their scores on trait anxiety (HTA or NHTA).

High trait anxiety

Women with HTA (N = 160) scored higher at all measurement moments on state anxiety, depressive symptoms, and lower on QoL compared with women with NHTA (P < 0.001; Table 2). Within the group with HTA, women in the PL and ASM groups scored similar on state anxiety, depressive symptoms, and QoL (Table 2; Figs. 1, 2). In both groups, scores on depressive symptoms decreased significantly at 1 month compared with scores at referral (P < 0.001). The only difference was a higher score on psychological QoL at referral in the ASM group (P = 0.029).

Not-high trait anxiety

In women with NHTA (N = 604), higher scores on state anxiety at referral were found in the ASM group compared with the PL group (P = 0.047). During follow-up, these scores significantly diminished after 1 month compared with the scores at referral in both groups (P < 0.001; Table 2; Fig. 1), and the scores remained similar until 6 months compared with 1 month, without differences between groups. Scores on depressive symptoms were higher in ASM at referral compared with PL (P < 0.001; Table 2; Fig. 2). In both groups, scores after 1 month remained similar during follow-up. Concerning QoL, women in the ASM group scored lower on psychological QoL at referral (P = 0.022) and at 12 months (P = 0.005) compared with the PL group.

Discussion

The discussion concerning the disadvantages of the BC screening program, such as false-positive findings, is still
ongoing and contributing to the screening controversy [14, 15]. The adverse psychological consequences after a false-positive screening mammogram are already described before [7–11, 16]. However, to our knowledge, a comparison between women with BBD referred after ASM or PL has not yet been performed. We hypothesized that women referred after ASM experience more adverse psychological effects compared with women referred with PL. As previously found, the negative effects in our study were strengthened by the personality characteristic trait anxiety, i.e., women with HTA scored unfavorably on state anxiety, depressive symptoms, and QoL, compared with women not prone to anxiety [6, 10, 12]. Before diagnosis was known, all women scored higher on state anxiety and depressive symptoms compared with 1 month after diagnosis, when women were relieved that BC was not found.

Table 1 Demographic and psychological characteristics comparing two groups: women with benign breast disease referred with an abnormal screening mammogram (ASM) or with a palpable lump in breast (PL)

| Demographics                                      | ASM (n = 363) | PL (n = 401) | P value |
|---------------------------------------------------|---------------|--------------|---------|
| Mean age (SD)                                     | 56.2 (6.8)    | 46.5 (10.9)  | <0.001 |
| Partner n (%)                                     | 308 (85)      | 348 (87)     | 0.315  |
| Children n (%)                                    | 315 (88)      | 322 (81)     | 0.009  |
| Education low/ moderate n (%)                     | 290 (80)      | 306 (76)     | 0.053  |
| Paid work n (%)                                   | 194 (54)      | 289 (72)     | <0.001 |

Table 2 Scores at referral and during follow up on state anxiety, depressive symptoms, and general quality of life (QoL) comparing four groups based on referral after abnormal screening program (ASM) or with palpable lump in breast (PL) and high trait anxiety (HTA) or not-high trait anxiety (NHTA)

| Mean scores (SD) HTA* | ASM (n = 75) | PL (n = 85) | P value |
|-----------------------|--------------|-------------|---------|
|                       | At referral  | 6 months    | At referral  | 6 months    |         |
| State anxiety         | 15.7 (3.4)   | 13.1 (3.6)  | 15.5 (3.5)   | 13.2 (3.6)  | NS      |
| Depressive symptoms   | 15.8 (9.3)   | 11.4 (9.3)b | 14.7 (9.6)   | 12.3 (8.8)b | NS      |
|                       | At referral  | 12 months   | At referral  | 12 months   |         |
| General QoL           | 6.9 (1.4)    | 6.9 (1.6)   | 6.7 (1.5)    | 6.7 (1.3)   | NS      |

| NHTA*                 | ASM n = 288  | PL n = 316  | P value |
|-----------------------|--------------|-------------|---------|
|                       | At referral  | 6 months    | At referral  | 6 months    |         |
| State anxiety         | 12.2 (3.9)   | 9.7 (3.0)b  | 11.6 (3.4)   | 9.7 (3.1)b  | R 0.047 |
| Depressive symptoms   | 7.0 (6.8)    | 5.3 (5.6)   | 5.2 (5.4)    | 4.4 (5.4)   | R < 0.001 |
|                       | At referral  | 12 months   | At referral  | 12 months   |         |
| General QoL           | 8.1 (1.4)    | 8.0 (1.3)   | 8.2 (1.2)    | 8.3 (1.2)   | NS      |

P value <0.05 considered significant. SD standard deviation, NS not significant, R significant difference at referral comparing ASM and PL

* All values in the HTA groups are significant different compared with NHTA groups (P < 0.001)

* Scores significantly changed at 6 months compared with scores at referral
In addition, we have found that within women not prone to anxiety, those in the ASM group were more anxious before diagnosis was known and experienced more depressive symptoms at referral compared with all women with PL. In addition, those women reported impaired psychological QoL at referral and 1 year after diagnosis compared with PL. In chronically anxious women higher scores on depressive symptoms at referral were found compared with 1 month after diagnosis, regardless of being referred after an ASM or with a PL.

Thus, the negative impact of a false-positive screening mammogram on anxiety, depressive symptoms, and QoL is especially found in women who do not have a high propensity for anxiety, confirming our previous findings [16]. These effects cannot be considered as a normal response to the diagnostic work up for breast disease, because not every woman responds similar to the threat of possibly having BC. The fact that women not prone to anxiety are affected more implies that being recalled for further diagnostic procedures after an ASM is a serious psychological problem, especially because the adverse effects persist at least 1 year after the diagnostic process showed by the lowered QoL.

The present findings contribute to the ongoing screening controversy: are the advantages of the BC screening program still in balance with the disadvantages? Recent data has suggested that screening has little detectable impact on BC mortality [25]. In addition, several publications have discussed the benefits and harms of the BC screening program [14, 15, 26–31]. Currently the decision to participate in the BC screening program is based upon information in favor of screening. The risk for possible adverse psychological consequences, overdiagnosis and overtreatment are not mentioned in the provided information [14, 28–30, 32, 33].

**Conclusions**

This study reveals that women recalled after an ASM experience higher state anxiety and depressive symptoms at referral with lowered QoL 1 year after diagnosis, compared with women with a PL, especially women not prone to anxiety. Therefore, we recommend that women should be informed properly concerning the benefits and risks of the BC screening program, in particular mentioning the adverse psychological consequences after a false-positive screening mammogram. In addition, at intake women should be offered a psychometric test to identify those who are at risk for impaired QoL.

**Ethical standards**

The study was approved by the Medical Ethical Committee.
Acknowledgments The authors acknowledge W. F. Schreurs, C. L. H. van Berlo, and F. W. C. van der Ent for their help in patient accrual. The authors are grateful to E. M. Harrison for reviewing the manuscript.

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. National Cancer Institute (2011) Probability of breast cancer in American women. http://www.cancer.gov/cancertopics/factsheet/Detection/probability-breast-cancer. Accessed 28 Sep 2011
2. Integraal Kanker Centrum Nederland (2011) Meest voorkomende kankersoorten in Nederland. http://www.ikcnet.nl/page.php?id=2985&nav_id=114. Accessed 28 Sep 2011
3. Van Esch L, Den Oudsten BL, De Vries J (2011) The World Health Organization quality of life instrument—short form (WHOQOL-BREF) in women with breast problems. Int J Clin Health Psychol 11:5–22
4. Meechan GT, Collins JP, Moss-Morris RE, Petrie KJ (2005) Who is not reassured following benign diagnosis of breast symptoms? Psychooncology 14:239–246
5. Woodward V, Webb C (2001) Women’s anxieties surrounding breast disorders: a systematic review of the literature. J Adv Nurs 33:29–41
6. Ando N, Iwamitsu Y, Kuranami M, Okazaki S, Nakatani Y, Yamamoto K, Watanabe M, Miyaoka H (2011) Predictors for psychological distress after diagnosis in breast cancer patients and patients with benign breast problems. Psychosomatics 52:56–64
7. Brett J, Bankhead C, Henderson B, Watson E, Austoker J (2005) The psychological impact of mammographic screening. A systematic review. Psychooncology 14:917–938
8. Brewer NT, Salz T, Lillie SE (2007) Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 146:502–510
9. Salz T, Richman AR, Brewer NT (2010) Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. Psychooncology 19:1026–1034
10. Van der Steeg AFW, Keyzer-Dekker CMG, De Vries J, Roukema JA (2011) Effect of abnormal screening mammogram on quality of life. Br J Surg 98:537–542
11. Hafslund B, Nortvedt MW (2009) Mammography screening from the perspective of quality of life: a review of the literature. Scand J Caring Sci. doi:10.1111/j.1471-6712.2008.00634.x
12. Montgomery M, McCrone SH (2010) Psychological distress associated with the diagnostic phase for suspected breast cancer: systematic review. J Adv Nurs 66:2372–2390
13. Spielberger CD, Gorsuch RL, Lushene RE (1970) The state-trait anxiety inventory manual. Consulting Psychologists Press, Palo Alto
14. Gotzsche PC, Nielsen M (2011) Screening for breast cancer with mammography. Cochrane Database Syst Rev 1:CD001877
15. Feig SA (2004) Adverse effects of screening mammography. Radiol Clin North Am 42:807–819
16. Keyzer-Dekker CMG, De Vries J, Van Esch L, Ernst MF, Niewenhuizen GA, Roukema JA, Van der Steeg AFW (2011) Anxiety after a false positive screenings mammogram is a serious problem. Breast (Epub ahead of print)
17. National Institute for Public Health and the Environment (2011) The Netherlands. http://www.rivm.nl. Accessed 28 Sep 2011
18. Van der Ploeg HM, De Vries J, Roukema JA, Van der Steeg AFW (2011) Anxiety after a false positive screenings mammogram is a serious problem. Breast (Epub ahead of print)
19. Van der Bij AK, De Weerd S, Cikot RJ, Steegers EA, Braspennings JC (2003) Validation of the Dutch short form of the state scale of the Spielberger state-trait anxiety inventory: considerations for usage in screening outcomes. Community Genet 6:84–87
20. Bogaarts MP, Den Oudsten BL, Roukema JA, Van Riel JM, Beerepoot LV, De Vries J (2011) Development of the psychosocial distress questionnaire-breast cancer (PDQ-BC): a breast cancer-specific screening instrument for psychosocial problems. Support Care Cancer 19:1485–1493
21. Schroovers MJ, Sanderman R, van Sonderen E, Ranchor AV (2000) The evaluation of the Center for epidemiologic studies depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Qual Life Res 9:1015–1029
22. Hann D, Winter K, Jacobsen P (1999) Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 46:437–443
23. WHOQOL Group (1998) Development of the world health organization WHOQOL-bref quality of life assessment. Psychol Med 28:551–558
24. De Vries J, Van Heck GL (1995) De Nederlandse versie van de WHOQOL-100 (The Dutch version of the WHOQOL-100). Tilburg University, Tilburg
25. Autier P, Boniol M, Gavin A, Vatten LJ (2011) Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343:d4411. doi:10.1136/bmj.d4411
26. McPherson K (2010) Screening for breast cancer—balancing the debate. BMJ 340:c3106
27. Welch HG (2010) Screening mammography—a long run for a short slide? N Engl J Med 363:1276–1278
28. Bonneux L (2009) Advantages and disadvantages of breast cancer screening: time for evidence-based information. Ned Tijdschr Geneeskd 153:A887
29. Baines CJ (2005) Are there downsides to mammography screening? Breast J 11:S7–S10
30. Thornton H, Edwards A, Baum M (2003) Women need better information about routine mammography. BMJ 327:101–103
31. Welch HG, Frankel BA (2011) Likelihood that a woman with screen-detected breast cancer has had her “life saved” by that screening. Arch Intern Med 171:2043–2046
32. Slator EK, Ward JE (1998) How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets. BMJ 317:263–264
33. Jorgensen KJ, Gotzsche P (2004) Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ 328:148–154